ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0290

Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
Abstract Number: 2056

Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
Abstract Number: 0662

Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
Abstract Number: 1137

Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
Abstract Number: 1921

Devastating Morbidity and Mortality Rates in the Hmong Population with a Diagnosis of Gout Who Had a COVID-19 Infection
Abstract Number: 2660

Developing Predictive Models for the Diagnosis of VEXAS Syndrome
Abstract Number: 2326

Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
Abstract Number: 0796

Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Abstract Number: 0316

Development and Evaluation of the Adult-onset Still’s Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment
Abstract Number: 1406

Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease
Abstract Number: 1255

Development and Validation of a Brief Measure of Uncertainty Among Patients with Vasculitis and Other Rheumatic Diseases
Abstract Number: 2627

Development and Validation of a Novel Score System to Guide Diagnostic Procedures in Children with Concerns of Chronic Nonbacterial Osteomyelitis
Abstract Number: 0368

Development and Validation of a Patient-centered Self-evaluation Questionnaire in Systemic Lupus Erythematosus: LUPIN®
Abstract Number: 1968

Development and Validation of an Arthritis-Detection Algorithm Using Thermal Imaging in Adults and Children
Abstract Number: 2280

Development of a Blood-based Cell-free DNA Classifier Assay to Predict Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients (PRIMA-102)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].